OGT inhibitor and application thereof

Abstract

The invention relates to an OGT inhibitor and application thereof. The invention provides an application of an OGT inhibitor in prevention or treatment of myeloblastoma or inhibition of cell proliferation of myeloblastoma. In a specific embodiment, the OGT inhibitor can inhibit the generation and cell proliferation of the medulloblastoma, which indicates that the OGT inhibitor has good medicinal potential in the aspect of preventing or treating the medulloblastoma. The invention also provides a method for screening candidate drugs for preventing or treating myeloblastoma or inhibiting cell proliferation of myeloblastoma.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to an OGT inhibitor and its application. Background technique [0002] Medulloblastoma (MB) is a malignant tumor of the posterior cranial fossa, often originating from the vermis of the cerebellum or the posterior medullary velum. The tumor cells grow very rapidly and have a high ability to invade and migrate, and it is very easy to circulate through the cerebrospinal fluid. Spread throughout the central nervous system. MB is the most common intracranial malignancy in children, accounting for 20% of central nervous system tumors in children, and double the proportion of cerebellar tumors in children, up to 40%. The incidence rate of European and American whites is higher than that of Asians. There are more men than women in the affected population. The peak age is 8 years old, and most of them occur before 20 years old. [0003] In 2007, the World Health Organization (WHO) d...

AI Technical Summary

Problems solved by technology

However, due to the special location of myeloblastoma and the young age of the patient, the operation is very difficult, and it is difficult to completely remove the tumor. As a result, the tumor is prone to recurrence after surgery, and the prognosis of the patient is poor, which seriously affects the health of the patient. survival rate is still low

Therefore, in addition to surgical resection, combined therapy often supplemented with postoperative radiotherapy can significantly improve the patient's survival rate and reduce the postoperative recurrence rate, but it may be accompanied by long-term toxic and side effects of the central nervous system of the patient. , such as hearing loss, cognitive impairment, neurological and mental retardation, etc.

Images